Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Glioblastoma 2Breast Neoplasms 2Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 5Radiotherapy 4Radiation 3Radiotherapy, Conformal 2Platinum 2Pemetrexed 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cisplatin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1methoxyamine 1lazertinib 1durvalumab 1capmatinib 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Metformin 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × veliparib × 30 days × Clear all
NCT01386385 2026-05-26

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
53 enrolled 21 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡